EBS

EBS R&D Expenses

$45.30MTTM · USD

Period ending:

EBS FY R&D ExpensesUSD
EBS FY R&D Expenses2001-12-31: $193.00M2002-12-31: $2.81M2003-12-31: $0.002004-12-31: $10.12M2005-12-31: $18.38M2006-12-31: $45.50M2007-12-31: $53.96M2008-12-31: $59.47M2009-12-31: $74.59M2010-12-31: $89.30M2011-12-31: $124.83M2012-12-31: $129.83M2013-12-31: $119.93M2014-12-31: $104.72M2015-12-31: $119.19M2016-12-31: $106.90M2017-12-31: $97.40M2018-12-31: $142.80M2019-12-31: $226.20M2020-12-31: $237.90M2021-12-31: $235.20M2022-12-31: $188.30M2023-12-31: $111.40M2024-12-31: $70.70M2025-12-31: $53.80M$237.90M$0.00
2001-12-312025-12-31

Source: Financial Modeling Prep (FMP). Annual fiscal periods; reported in USD. Dates are period ends; a fiscal year may differ from a calendar year.

EBS r&d expenses history

Research and development spending. The available annual fiscal periods series contains 25 observations from Dec 31, 2001 to Dec 31, 2025.

Emergent Biosolutions Inc R&D Expenses — Annual fiscal periods (USD)
Period endingR&D Expenses (USD)
53,800,000
70,700,000
111,400,000
188,300,000
235,200,000
237,900,000
226,200,000
142,800,000
97,400,000
106,900,000
119,186,000
104,721,000
119,933,000
129,826,000
124,832,000
89,295,000
74,588,000
59,470,000
53,958,000
45,501,000
18,381,000
10,117,000
0
2,808,000
193,000,000

Compare r&d expenses

All EBS financial metrics · EBS stock overview · How to interpret financial metrics

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.